A chromogenic kit for in vitro diagnostic determination of antithrombin activity in human plasma. The use of factor Xa in preference to thrombin eliminates interference from heparin cofactor II and thrombin inhibitors.

The FXa-based assay has been shown to discriminate better between AT-deficient and non-AT-deficient individuals than a thrombin-based assay [Demers et al 1993]. It also gives accurate results in patients who are receiving heparin therapy [Bohner et al 1994].

Simple, accurate and convenient. All methods are based on FXa inhibition. Allows accurate determination of antithrombin in patients receiving heparin therapy. Superior reagent stability. Validated and documented protocols for a wide range of instruments. Suitable for both large and small laboratories.

Features of Coamatic Antithrombin:

• Use of FXa instead of thrombin eliminates interference from heparin cofactor II anddirect thrombin inhibitors
• Highly sensitive FXa chromogenic substrate and superior reagent stability
• High accuracy and precision - CV values less than 5%
• Applications available for a wide range of automated coagulation analyzers, including the BCS
• Accurate determinations in patients receiving heparin therapy
• Suitable for both large and small laboratories

Antithrombin Pathway

Measurement principle

AT = Antithrombin

Reagents and Stability when opened

Number of determinations: 50 (test tube), 200 (microplate), up to 130 (automated)